Stock GTHR GENETHERA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials GeneThera, Inc.

Equities

GTHR

US37185E3062

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 11:44:13 20/02/2024 pm IST 		5-day change 1st Jan Change
0.000001 USD -99.98% Intraday chart for GeneThera, Inc. -.--% -.--%
2022 GeneThera, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
2022 GeneThera, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI

Valuation

Fiscal Period: December 2016 2017 2018 2019 2020 2021
Capitalization 1 0.601 0.4006 0.3325 0.1442 0.3418 0.9973
Enterprise Value (EV) 1 2.658 1.542 1.545 0.961 1.154 1.809
P/E ratio -0.71 x -0.53 x -0.08 x - -0.37 x -0.81 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA - - -3,93,869 x -13,09,495 x -15,69,235 x -18,01,372 x
EV / FCF - - 14,33,150 x 22,82,324 x 39,10,263 x 48,78,290 x
FCF Yield - - 0% 0% 0% 0%
Price to Book -0.08 x -0.06 x -0.04 x - -0.04 x -0.13 x
Nbr of stocks (in thousands) 40,065 40,065 40,065 40,065 24,071 30,971
Reference price 2 0.0150 0.0100 0.008300 - 0.0142 0.0322
Announcement Date 12/09/18 30/11/18 27/02/20 10/06/20 14/04/21 14/04/22
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2016 2017 2018 2019 2020 2021
Net sales - - - - - -
EBITDA - - -3.921 -0.7339 -0.7353 -1.004
EBIT 1 -0.6801 -0.6057 -3.927 -0.7392 -0.7406 -1.009
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -0.7789 -0.7577 -4.045 -0.5177 -0.7745 -1.011
Net income 1 -0.7789 -0.7577 -4.045 -0.5177 -0.7745 -1.011
Net margin - - - - - -
EPS 2 -0.0213 -0.0189 -0.1059 -0.0144 -0.0381 -0.0399
Free Cash Flow - - 1.078 0.4211 0.2951 0.3707
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 12/09/18 30/11/18 27/02/20 10/06/20 14/04/21 14/04/22
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2016 2017 2018 2019 2020 2021
Net Debt 1 2.06 1.14 1.21 0.82 0.81 0.81
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) - - -0.3091 x -1.113 x -1.104 x -0.8081 x
Free Cash Flow - - 1.08 0.42 0.3 0.37
ROE (net income / shareholders' equity) 11.4% 10.6% 53.5% 7.77% 10.6% 12.8%
ROA (Net income/ Total Assets) -582% -367% -2,010% -1,558% -2,828% -7,054%
Assets 1 0.1339 0.2062 0.2012 0.0332 0.0274 0.0143
Book Value Per Share 2 -0.1800 -0.1800 -0.2200 -0.1900 -0.3200 -0.2400
Cash Flow per Share - 0 0 0 - -
Capex - 0.03 - - - -
Capex / Sales - - - - - -
Announcement Date 12/09/18 30/11/18 27/02/20 10/06/20 14/04/21 14/04/22
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
GENETHERA, INC. Stock GeneThera, Inc.
-.--% 35
MODERNA, INC. Stock Moderna, Inc.
+33.63% 50.93B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.09% 42.12B
LONZA GROUP AG Stock Lonza Group AG
+49.62% 42.05B
CELLTRION, INC. Stock Celltrion, Inc.
-4.96% 29.18B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.18% 26.02B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.95% 18.9B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+8.61% 13.21B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.73% 12.17B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.31% 12.16B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. GTHR Stock
  4. Financials GeneThera, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW